Herpes simplex virus (HSV) infections in humans are responsible for a variety of syndromes ranging from fever blisters to viral encephalitis. HSV infections are frequent in cancer patients and in patients undergoing immunosuppression. Efforts to control HSV infections by immunological intervention have only been partially successful i the experimental host due to the ability to the virus to establish latent infection in the ganglia and to subsequently reactivate under a variety of conditions. Convincing evidence exists for a role of the immune response in virus clearance and elimination of virus infected cells. Both CD8+ and CD4+ T lymphocytes contribute to the immunological defense against HSV infections. The overall goal of this proposal is to predict and to localize the CTL recognition epitopes on proteins encoded by the HSV genome and to determine their ability to both function as target site for HSV-specific CTL and to induce immunological responses in vivo. The proposed studies are based on our understanding of MCH restriction, antigen processing involving protein degradation into peptides, and the presentation of peptides by MHC class I molecules to the T cell receptor. Using a mouse model, we will achieve our goal by predicting and localizing CTL epitopes coded for by the HSV genome and by identifying the dominant HSV CTL epitopes and determine the ability of these epitopes to confer protection against HSV primary infection and establishment of latent infection. In addition, we will express these synthetic peptides and HSV-specific CTL epitopes in heterologous proteins and in vaccinia virus recombinants as immunogens in which attempts will be made to enhance their immunogenicity in vivo by increasing the efficiency of antigen processing and presentation. Ultimately, these epitope-specific CTL will be examined for their ability to suppress viral pathogenicity and establishment of latency. The stability of HSV CTL epitopes under CTL selective pressure will also be determined. Together, these approaches will allow us to develop effective vaccine candidates for immune defense against HSV infection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI034070-04
Application #
2003938
Study Section
Experimental Virology Study Section (EVR)
Project Start
1993-12-01
Project End
1998-11-30
Budget Start
1996-12-01
Budget End
1997-11-30
Support Year
4
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Pennsylvania State University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
129348186
City
Hershey
State
PA
Country
United States
Zip Code
17033
Brehm, M; Samaniego, L A; Bonneau, R H et al. (1999) Immunogenicity of herpes simplex virus type 1 mutants containing deletions in one or more alpha-genes: ICP4, ICP27, ICP22, and ICP0. Virology 256:258-69
Boesteanu, A; Brehm, M; Mylin, L M et al. (1998) A molecular basis for how a single TCR interfaces multiple ligands. J Immunol 161:4719-27
Blaney Jr, J E; Nobusawa, E; Brehm, M A et al. (1998) Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity. J Virol 72:9567-74
Brehm, M A; Bonneau, R H; Knipe, D M et al. (1997) Immunization with a replication-deficient mutant of herpes simplex virus type 1 (HSV-1) induces a CD8+ cytotoxic T-lymphocyte response and confers a level of protection comparable to that of wild-type HSV-1. J Virol 71:3534-44
Bonneau, R H; Brehm, M A; Kern, A M (1997) The impact of psychological stress on the efficacy of anti-viral adoptive immunotherapy in an immunocompromised host. J Neuroimmunol 78:19-33
Fu, T M; Bonneau, R H; Epler, M et al. (1996) Induction and persistence of a cytotoxic T lymphocyte (CTL) response against a herpes simplex virus-specific CTL epitope expressed in a cellular protein. Virology 222:269-74
Salvucci, L A; Bonneau, R H; Tevethia, S S (1995) Polymorphism within the herpes simplex virus (HSV) ribonucleotide reductase large subunit (ICP6) confers type specificity for recognition by HSV type 1-specific cytotoxic T lymphocytes. J Virol 69:1122-31